What We Do
Galsat delivers an advanced and much simpler Asthma treatment using an oral delivery of Fidarestat, an aldose reductase inhibitor. The oral delivery capability of Fidarestat yields a higher medication compliance rate and delivery efficiency than traditional inhalers.
The Product
- Fidarestat tablets (PROTOTYPE)
- Fidarestat syrup (PROTOTYPE)
Target Customer Pain Points
- Patients, especially children, with cumbersome and minimally effective Asthma regimens including inhalers
- Hospitals and clinics should see fewer incidents of non-compliance and associated side effects
- Health Departments will see decreases in cost of care as a result of easier treatment and greater adherence to provider recommendations
Differentiation
- Convenience of taking pills and syrups as opposed to inhalers
- Safer administration with less risk of patients misusing (under or over-dosing) on Asthma medication
- Lower cost will encourage compliance for patients with the lifetime disease burden
Market Size
Each year, the cost of trea.ng Asthma in the United States is approximately 10% of all medications costs combined.
Progress & Milestones
- Developed and tested novel therapeutic drug to treat inflammatory disorders like Asthma
- Successfully tested in animal models; human clinical samples tested show high effectiveness in treating Asthma
- Phase II/III clinical trial studies in the US and Japan yielded no irreversible adverse events in patients
Management Team
- Satish Srivastava, PhD
- William Calhoun, MD
- Seprel Erzurum, PhD
- Alexander Vo, PhD
Download this document